| 3.905 -0.085 (-2.13%) | 05-13 13:11 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.13 | 1-year : | 6 |
| Resists | First : | 4.4 | Second : | 5.13 |
| Pivot price | 3.55  |
|||
| Supports | First : | 3.26 | Second : | 2.55 |
| MAs | MA(5) : | 3.91 |
MA(20) : | 3.41 |
| MA(100) : | 3.06  |
MA(250) : | 4.24 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 67.1 |
D(3) : | 66.7 |
| RSI | RSI(14): 65.1 |
|||
| 52-week | High : | 6.86 | Low : | 1.9 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TKNO ] has closed below upper band by 19.8%. Bollinger Bands are 28.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.1 - 4.12 | 4.12 - 4.14 |
| Low: | 3.7 - 3.73 | 3.73 - 3.76 |
| Close: | 3.95 - 3.99 | 3.99 - 4.03 |
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
Sat, 09 May 2026
Alpha Teknova, Inc. (NASDAQ:TKNO) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
Sat, 09 May 2026
Analyst Estimates: Here's What Brokers Think Of Alpha Teknova, Inc. (NASDAQ:TKNO) After Its First-Quarter Report - simplywall.st
Fri, 08 May 2026
Alpha Teknova (TKNO) Q1 Loss Of US$4.6 Million Reinforces Profitability Skepticism - Sahm
Fri, 08 May 2026
TKNO Stock Price, Quote & Chart | ALPHA TEKNOVA INC (NASDAQ:TKNO) - ChartMill
Thu, 07 May 2026
Alpha Teknova Charts Cautious Path to 2027 Growth - TipRanks
Thu, 07 May 2026
Alpha Teknova (NASDAQ: TKNO) lifts Q1 2026 revenue but remains unprofitable - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 54 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 9.3 (%) |
| Held by Institutions | 83.4 (%) |
| Shares Short | 1,330 (K) |
| Shares Short P.Month | 1,330 (K) |
| EPS | -0.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.27 |
| Profit Margin | -42.6 % |
| Operating Margin | -41.2 % |
| Return on Assets (ttm) | -9.3 % |
| Return on Equity (ttm) | -22.9 % |
| Qtrly Rev. Growth | 7.8 % |
| Gross Profit (p.s.) | 0.25 |
| Sales Per Share | 0.75 |
| EBITDA (p.s.) | -0.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -12.32 |
| PEG Ratio | 0 |
| Price to Book value | 3.07 |
| Price to Sales | 5.21 |
| Price to Cash Flow | -24.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|